Shield Therapeutics PLC Block Listing 6 Monthly Return (6311N)
30 Septiembre 2021 - 11:29AM
UK Regulatory
TIDMSTX
RNS Number : 6311N
Shield Therapeutics PLC
30 September 2021
Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 30 September 2021
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: S hield Therapeutics Retention Share Plan
----------------------------------------------
Period of return: From: 01 April 2021 To: 30 September 2021
------------------------ ----------------- ---- ---------------------
Balance of unallotted securities under scheme(s) from previous
return: 39,794
----------------------------------------------
Plus: The amount by which the block scheme(s) has been increased NIL
since the date of the last
return (if any increase has been applied for):
----------------------------------------------
Less: Number of securities issued/allotted under scheme(s) during NIL
period (see LR3.5.7G):
----------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of
period: 39,794
----------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics plc 2016 Company Share Option Plan
-----------------------------------------------------------
Period of return: From: 01 April 2021 To: 30 September 2021
------------------------ ---------------------- ------ ---------------------------
Balance of unallotted securities under scheme(s) from
previous return: 388,079
-----------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-----------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): -47,059
-----------------------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted
at end of period: 341,020
-----------------------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: The Shield Therapeutics plc 2016 Long Term Incentive Plan
-------------------------------------------------------------
Period of return: From: 01 April 2021 To: 30 September 2021
------------------------ ----------------------- ------ ----------------------------
Balance of unallotted securities under scheme(s) from
previous return: 24,273
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-------------------------------------------------------------
Less: Number of securities issued/allotted under NIL
scheme(s) during period (see LR3.5.7G):
-------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 24,273
-------------------------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics Retention and Performance Share Plan
-------------------------------------------------------------
Period of return: From: 01 April 2021 To: 30 September 2021
------------------------ ----------------------- ------ ----------------------------
Balance of unallotted securities under scheme(s) from
previous return: 3,178,276
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-------------------------------------------------------------
Less: Number of securities issued/allotted under NIL
scheme(s) during period (see LR3.5.7G):
-------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 3,178,276
-------------------------------------------------------------
Name of contact: Lucy Huntington-Bailey
Telephone number of contact: +44 (0) 191 511 8500
-----------------------
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Greg Madison (CEO)
Hans-Peter Rudolf (CFO)
Peel Hunt LLP - Nominated Adviser & Joint
Broker +44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane/ George Dollemore
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne/ Alice or shield@walbrookpr.com
Woodings
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK,
Switzerland and Australia and has exclusive IP rights until the
mid-2030s. The Group is currently launching Accrufer(R) in the US.
Feraccru(R) is already being commercialised in the UK and European
Union by Norgine B.V., who also have the marketing rights in
Australia and New Zealand. Shield also has an exclusive licence
agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialisation of Feraccru(R)/Accrufer(R) in
China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLREAKNEDAEFEFA
(END) Dow Jones Newswires
September 30, 2021 12:29 ET (16:29 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De May 2023 a May 2024